Quince Therapeutics (QNCX) executive compensation, 2026 proxy

Dirk Thye, Chief Executive Officer and Chief Medical Officer, was paid $2.5M in 2025, down 9% from $2.7M the year before.

Filed
August 25, 2026
Annual meeting
October 6, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.5M-9% vs prior year
Corporate objective achievement
107.5%Determined 2025 bonus payouts
Thye target bonus
50%Percentage of base salary
Ryan target bonus
40%Percentage of base salary
Hannah target bonus
40%Percentage of base salary
Thye retention bonus
$700,000Contingent on continued employment
Hannah retention bonus
$500,000Contingent on continued employment

How Thye was paid

$2.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary22%Option awards66%Non-equity incentive12%All other compensation0%

Named executive officers

ExecutiveTotal
Dirk ThyeChief Executive Officer and Chief Medical Officer$2,493,625
Charles RyanPresident$1,144,100
Brendan HannahChief Operating Officer, Chief Business Officer and Chief Compliance Officer$1,263,075

What changed and why

  • $2.5M$2,493,625 was CEO total compensation in 2025, down from $2,732,125 in 2024.
  • $1.6M$1,644,000 was the CEO’s 2025 option award value, compared with $1,965,000 in 2024.
  • 107.5%107.5% of corporate objectives were achieved for 2025, determining the executives’ bonus payouts.
  • 50%50%, 40%, and 40% were the 2025 target bonuses for Thye, Ryan, and Hannah, respectively.
  • $700K$700,000 and $500,000 retention bonuses were approved for Thye and Hannah, contingent on continued employment.
  • $21,600$21,600 of Ryan’s all-other compensation represented health insurance premiums.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.